JP2022535972A5 - - Google Patents
Info
- Publication number
- JP2022535972A5 JP2022535972A5 JP2021573569A JP2021573569A JP2022535972A5 JP 2022535972 A5 JP2022535972 A5 JP 2022535972A5 JP 2021573569 A JP2021573569 A JP 2021573569A JP 2021573569 A JP2021573569 A JP 2021573569A JP 2022535972 A5 JP2022535972 A5 JP 2022535972A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962860182P | 2019-06-11 | 2019-06-11 | |
| US62/860,182 | 2019-06-11 | ||
| US201962924356P | 2019-10-22 | 2019-10-22 | |
| US62/924,356 | 2019-10-22 | ||
| US201962932160P | 2019-11-07 | 2019-11-07 | |
| US62/932,160 | 2019-11-07 | ||
| PCT/EP2020/066234 WO2020249693A1 (en) | 2019-06-11 | 2020-06-11 | Compositions and methods for subcutaneous administration of cancer immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535972A JP2022535972A (ja) | 2022-08-10 |
| JP2022535972A5 true JP2022535972A5 (https=) | 2023-06-20 |
| JPWO2020249693A5 JPWO2020249693A5 (https=) | 2023-06-20 |
Family
ID=71092539
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573569A Pending JP2022535972A (ja) | 2019-06-11 | 2020-06-11 | がん免疫療法の皮下投与のための組成物及び方法 |
| JP2021573568A Pending JP2022535610A (ja) | 2019-06-11 | 2020-06-11 | がん免疫療法のための組成物及び方法 |
| JP2025061430A Pending JP2025107180A (ja) | 2019-06-11 | 2025-04-02 | がん免疫療法のための組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573568A Pending JP2022535610A (ja) | 2019-06-11 | 2020-06-11 | がん免疫療法のための組成物及び方法 |
| JP2025061430A Pending JP2025107180A (ja) | 2019-06-11 | 2025-04-02 | がん免疫療法のための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US11246906B2 (https=) |
| EP (2) | EP3983530A1 (https=) |
| JP (3) | JP2022535972A (https=) |
| KR (2) | KR20220044480A (https=) |
| CN (2) | CN114423446A (https=) |
| AU (2) | AU2020292590A1 (https=) |
| BR (2) | BR112021025035A2 (https=) |
| CA (2) | CA3143098A1 (https=) |
| IL (2) | IL288754A (https=) |
| MA (1) | MA56176A (https=) |
| MX (2) | MX2021015354A (https=) |
| WO (2) | WO2020249687A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246906B2 (en) | 2019-06-11 | 2022-02-15 | Alkermes Pharma Ireland Limited | Compositions and methods for subcutaneous administration of cancer immunotherapy |
| MX2022004577A (es) * | 2019-10-18 | 2022-05-10 | Alkermes Pharma Ireland Ltd | Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune. |
| KR20230016178A (ko) * | 2020-04-15 | 2023-02-01 | 엘커메스 파마 아일랜드 리미티드 | 혈관신생 억제제와 조합된 면역자극제 |
| MX2022012982A (es) * | 2020-04-15 | 2023-03-06 | Alkermes Pharma Ireland Ltd | Agentes inmunoestimulantes en combinación con inhibidores de la angiogénesis. |
| US12159700B2 (en) | 2020-04-22 | 2024-12-03 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| EP4146794A1 (en) | 2020-05-04 | 2023-03-15 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| TW202208616A (zh) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | 改良之腫瘤反應性ｔ細胞的選擇 |
| AU2021270745A1 (en) * | 2020-05-11 | 2022-12-15 | Mural Oncology, Inc. | IL-2 fusion polypeptide compositions and methods of making and using the same |
| US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| TW202241468A (zh) | 2020-12-11 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者 |
| CA3202483A1 (en) | 2020-12-17 | 2022-06-23 | Maria Fardis | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| US20240123067A1 (en) | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
| TW202242085A (zh) | 2020-12-31 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 供自動生產腫瘤浸潤淋巴球的裝置和方法 |
| TW202241508A (zh) | 2021-01-29 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法 |
| CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
| WO2022187741A2 (en) | 2021-03-05 | 2022-09-09 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
| WO2022198141A1 (en) | 2021-03-19 | 2022-09-22 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
| AU2022246174A1 (en) | 2021-03-25 | 2023-09-14 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
| MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
| WO2022212948A1 (en) * | 2021-04-02 | 2022-10-06 | Duke University | Methods for determining tumor immune status |
| EP4326287A2 (en) | 2021-04-19 | 2024-02-28 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| US20240365776A1 (en) | 2021-07-22 | 2024-11-07 | Iovance Biotherapeutics, Inc | Method for cryopreservation of solid tumor fragments |
| US20240342285A1 (en) | 2021-07-28 | 2024-10-17 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
| IL311333A (en) | 2021-09-09 | 2024-05-01 | Iovance Biotherapeutics Inc | Processes for generating til products using pd-1 talen knockdown |
| EP4404969A1 (en) | 2021-09-24 | 2024-07-31 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
| WO2023077015A2 (en) | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| EP4430167A1 (en) | 2021-11-10 | 2024-09-18 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| US20250101380A1 (en) | 2022-01-28 | 2025-03-27 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
| CN118891055A (zh) * | 2022-02-11 | 2024-11-01 | 穆拉肿瘤公司 | 用于癌症免疫疗法的组合物和方法 |
| EP4241791A1 (en) | 2022-03-07 | 2023-09-13 | InnaTher Gene Therapy S.à.r.l. | Combined gene and radio therapy for the treatment of cancer |
| EP4241790A1 (en) | 2022-03-07 | 2023-09-13 | InnaTher Gene Therapy S.à.r.l. | Expression system for the treatment of cancer |
| EP4504220A1 (en) | 2022-04-06 | 2025-02-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| CA3248034A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT |
| EP4522202A1 (en) | 2022-05-10 | 2025-03-19 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
| US20260008990A1 (en) | 2022-07-06 | 2026-01-08 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
| CN117003852B (zh) * | 2022-07-07 | 2024-11-05 | 北京大学 | 白细胞介素-2的拓扑改造及其作为自身免疫病药物的应用 |
| EP4565683A1 (en) | 2022-08-01 | 2025-06-11 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| EP4583890A1 (en) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| EP4583889A1 (en) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| WO2024098027A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
| EP4623072A2 (en) | 2022-11-21 | 2025-10-01 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| AU2024296516A1 (en) | 2023-07-13 | 2026-01-22 | Iovance Biotherapeutics, Inc. | Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes |
| AU2024292473A1 (en) | 2023-07-19 | 2026-01-29 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc |
| WO2025054540A1 (en) | 2023-09-08 | 2025-03-13 | Iovance Biotherapeutics, Inc. | Methods of gene-editing using programmable nucleases |
| WO2025101484A1 (en) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
| WO2025171182A1 (en) | 2024-02-08 | 2025-08-14 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine |
| WO2026006784A1 (en) | 2024-06-28 | 2026-01-02 | Iovance Biotherapeutics, Inc. | Methods of making tumor reactive peripheral blood lymphocytes (trpbl) |
| WO2026035866A1 (en) | 2024-08-07 | 2026-02-12 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor |
| WO2026072794A2 (en) | 2024-09-26 | 2026-04-02 | Iovance Biotherapeutics, Inc. | Expansion processes for til product enriched with neoantigen- reactive t cells (narts) |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766920A (en) | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| CN1007907B (zh) * | 1985-04-30 | 1990-05-09 | 弗·哈夫曼-拉罗彻有限公司 | 重组人类白细胞介素-2的提纯 |
| AU7873187A (en) | 1986-08-08 | 1988-02-24 | University Of Minnesota | Method of culturing leukocytes |
| US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| DE69430315T2 (de) | 1993-08-06 | 2002-11-21 | Epimmune, Inc. | Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| JP3926842B2 (ja) | 1995-03-08 | 2007-06-06 | ザ・スクリプス・リサーチ・インステイチユート | 抗原提示系およびｔ−細胞の活性化方法 |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| WO1998033891A1 (en) | 1997-01-31 | 1998-08-06 | Hemosol Inc. | Method for the production of selected lymphocytes |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| NZ521070A (en) | 2000-03-02 | 2004-07-30 | Univ Southern California | Mutated cyclin G1 protein |
| NZ530212A (en) | 2001-06-13 | 2006-09-29 | Genmab As | An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR) |
| AU2002360335A1 (en) | 2001-11-01 | 2003-05-12 | The Regents Of The University Of Michigan | Small molecule inhibitors targeted at bcl-2 |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US7435592B2 (en) | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| CA2762015A1 (en) | 2003-08-04 | 2005-02-24 | Bristol-Myers Squibb Company | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| US20060057121A1 (en) | 2004-09-10 | 2006-03-16 | Demao Yang | Compositions and treatments using ex vivo activated cells for myelosuppressed patients |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2647835A1 (en) * | 2006-03-28 | 2007-10-04 | Neopro Labs, Llc | Methods and compositions for treating conditions |
| KR101456728B1 (ko) | 2006-09-08 | 2014-10-31 | 메디뮨 엘엘씨 | 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009100140A1 (en) | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| JP5794917B2 (ja) | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ | Ｐｄ−１特異抗体およびその使用 |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| RS61391B1 (sr) * | 2012-06-08 | 2021-02-26 | Alkermes Pharma Ireland Ltd | Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti |
| DK2986312T3 (da) * | 2013-04-19 | 2022-02-14 | Cytune Pharma | Cytokinafledt behandling med reduceret vaskulært lækagesyndrom |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| MA40094B1 (fr) * | 2014-08-06 | 2022-05-31 | Univ Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
| AU2015364396B2 (en) * | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| CN106552259B (zh) * | 2015-09-24 | 2022-03-29 | 中国科学院上海巴斯德研究所 | 一种融合蛋白及其治疗疾病的用途 |
| GB201712032D0 (en) * | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| AU2018364752A1 (en) | 2017-11-13 | 2020-05-28 | Bioxcel Therapeutics, Inc. | Methods and compositions for treating cancer by modifying multiple arms of the immune system |
| US11246906B2 (en) | 2019-06-11 | 2022-02-15 | Alkermes Pharma Ireland Limited | Compositions and methods for subcutaneous administration of cancer immunotherapy |
| US20230372397A1 (en) * | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
-
2020
- 2020-06-10 US US16/897,920 patent/US11246906B2/en not_active Expired - Fee Related
- 2020-06-10 US US16/898,008 patent/US20210038684A1/en active Pending
- 2020-06-11 EP EP20732575.4A patent/EP3983530A1/en not_active Withdrawn
- 2020-06-11 CA CA3143098A patent/CA3143098A1/en not_active Abandoned
- 2020-06-11 JP JP2021573569A patent/JP2022535972A/ja active Pending
- 2020-06-11 BR BR112021025035A patent/BR112021025035A2/pt unknown
- 2020-06-11 MX MX2021015354A patent/MX2021015354A/es unknown
- 2020-06-11 CN CN202080055682.XA patent/CN114423446A/zh active Pending
- 2020-06-11 AU AU2020292590A patent/AU2020292590A1/en active Pending
- 2020-06-11 CA CA3143097A patent/CA3143097A1/en active Pending
- 2020-06-11 EP EP20732576.2A patent/EP3982998A1/en not_active Ceased
- 2020-06-11 CN CN202080056860.0A patent/CN114555126A/zh active Pending
- 2020-06-11 WO PCT/EP2020/066226 patent/WO2020249687A1/en not_active Ceased
- 2020-06-11 KR KR1020227000547A patent/KR20220044480A/ko not_active Ceased
- 2020-06-11 AU AU2020291109A patent/AU2020291109A1/en active Pending
- 2020-06-11 MA MA056176A patent/MA56176A/fr unknown
- 2020-06-11 WO PCT/EP2020/066234 patent/WO2020249693A1/en not_active Ceased
- 2020-06-11 BR BR112021024966A patent/BR112021024966A2/pt not_active IP Right Cessation
- 2020-06-11 MX MX2021015353A patent/MX2021015353A/es unknown
- 2020-06-11 KR KR1020227000553A patent/KR20220044481A/ko not_active Ceased
- 2020-06-11 JP JP2021573568A patent/JP2022535610A/ja active Pending
-
2021
- 2021-12-07 IL IL288754A patent/IL288754A/en unknown
- 2021-12-07 IL IL288756A patent/IL288756A/en unknown
-
2022
- 2022-01-04 US US17/568,251 patent/US11980652B2/en active Active
-
2024
- 2024-05-10 US US18/660,534 patent/US20250000938A1/en active Pending
-
2025
- 2025-04-02 JP JP2025061430A patent/JP2025107180A/ja active Pending